Paper Details
- Home
- Paper Details
Successful continuance of CDK4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report.
Author: FujimiyaTatsuhiro, HyasashiSeiichi, KusanoJunichi, OkazawaAkira, OzawaYuki, ShimadaAkihiko, YamamotoRyusei
Original Abstract of the Article :
Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, causes severe hepatotoxicity, a severe adverse event associated with the loss of treatment opportunities. We report a case of liver injury (grade 4) during treatment with abemaciclib, in which the patient was switched to palbociclib and ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://pubmed.ncbi.nlm.nih.gov/37578747
データ提供：米国国立医学図書館（NLM）
Navigating the Challenges of CDK4/6 Inhibitor Therapy in Breast Cancer
The treatment of breast cancer is a complex and ever-evolving field, with new therapies constantly emerging. This case report highlights the challenge of managing hepatotoxicity associated with CDK4/6 inhibitors, specifically abemaciclib. The report describes a patient who experienced severe hepatotoxicity during treatment with abemaciclib but was successfully transitioned to palbociclib, demonstrating the potential for continued CDK4/6 inhibitor therapy in cases of abemaciclib-induced hepatotoxicity.
A New Path Forward: Managing Hepatotoxicity with CDK4/6 Inhibitors
This case report offers a valuable perspective on the management of hepatotoxicity associated with CDK4/6 inhibitors. The findings suggest that in cases of abemaciclib-induced hepatotoxicity, switching to palbociclib may provide a viable option for continuing CDK4/6 inhibitor therapy. It's like discovering a hidden oasis in the vast desert of breast cancer treatment, offering a source of hope for patients facing this challenge.
A Journey Through Treatment Options: Finding the Right Path for Breast Cancer
This case report underscores the importance of individualized treatment approaches for breast cancer. It highlights the need for careful monitoring of drug side effects and the potential for adjusting treatment strategies based on individual patient responses. It's like navigating a desert, where the path to recovery may require adjustments and adaptations to reach the desired destination.
Dr. Camel's Conclusion
This case report provides a valuable insight into the management of hepatotoxicity associated with CDK4/6 inhibitors. It highlights the importance of ongoing research and careful monitoring to optimize treatment strategies for breast cancer patients. It's like a camel caravan traversing a vast desert, seeking to find the most effective and compassionate approaches to care for patients facing health challenges.
Date :
- Date Completed n.d.
- Date Revised 2023-08-14
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.